A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial

American Journal of Kidney Diseases

Volumn 67, Issue 6, 2016, Pages 861-871

  Brigandi, Richard A ^a   Johnson, Brendan ^a   Oei, Coreen ^a   Westerman, Mark ^b   Olbina, Gordana ^b   De Zoysa, Janak ^c   Roger, Simon D ^d   Sahay, Manisha ^e   Cross, Nicholas ^f   McMahon, Lawrence ^g   Guptha, Veerabhadra ^h   Smolyarchuk, Elena A ⁱ   Singh, Narinder ^j   Russ, Steven F ^a   Kumar, Sanjay ^a   Borsukov, Alexey V ^k   Marasaev, Vyacheslav V ^k   Prasad, Gullipalli ^k   Timokhovskaya, Galina Y ^k   Kolmakova, Elena V ^k   Dobronravov, Vladimir A ^k   Zakharova, Elena V ^k   Abraham, Georgi ^k   Packham, David ^k   Zateyshchikov, Dmitry A ^k   Arutyunov, Gregory P ^k   Volgina, Galina V ^k   Lipatov, Kirill S ^k   Perlin, Dmitry V ^k   Cooper, Bruce ^k   Kumar Saha, Tarun ^k   Zagrebelnaya, Olga A ^k   Mehta, Kalpana S ^k   Koziolova, Natalya A ^k   Fassett, Rob ^k   Alexeeva, Narina P ^k   Lysenko, Lidia V ^k   more..

^a GLAXOSMITHKLINE   (United States)

^b Intrinsic Life Sciences   (United States)

^c NORTH SHORE HOSPITAL   (New Zealand)

^d Renal Research   (Australia)

^e OSMANIA GENERAL HOSPITAL   (India)

^f Christchurch Hospital   (United States)

^g MONASH UNIVERSITY   (Australia)

^h Sri Research for Tissue Engineering Pvt Ltd   (India)

ⁱ A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^j Pushpanjali Crosslay Hospital   (India)

^k Pushpanjali Crosslay Hospital ^*

more..

Author keywords

chronic kidney disease (CKD); dialysis; dosing; erythropoiesis stimulating agent (ESA); Erythropoietin (EPO); hemoglobin; hemoglobin response rate; hepcidin; hypoxia inducible factor (HIF); pharmacodynamics; pharmacokinetics; phase II; prolyl hydroxylase inhibitor (PHI); randomized controlled trial (RCT); reticulocyte count

Indexed keywords

DAPRODUSTAT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; PLACEBO; BARBITURIC ACID DERIVATIVE; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; PROLYL HYDROXYLASE INHIBITOR;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRITIS; ARTICLE; ATRIAL FIBRILLATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROPOIESIS; FEMALE; FEVER; HEADACHE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; IRON BINDING CAPACITY; KIDNEY DYSFUNCTION; LETHARGY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY FAILURE; RETICULOCYTE COUNT; SCIATICA; SIDE EFFECT; SINGLE BLIND PROCEDURE; THORAX PAIN; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BARBITURATES; FEMALE; GLYCINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MIDDLE AGED; PROLYL-HYDROXYLASE INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; SINGLE-BLIND METHOD; TIME FACTORS; YOUNG ADULT;

EID: 84962073517     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.11.021     Document Type: Article

References (27)

1. National Kidney Foundation. KDOQI guidelines, executive summaries of 2000 updates. www.kidney.org/news/newsroom/newsreleases/0173. Accessed September 12, 2014.
2. R.J. McGonigle, J.D. Wallin, R.K. Shadduck, and J.W. Fisher Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency Kidney Int 25 2 1984 437 444
3. J.W. Eschbach, and J.W. Adamson Anemia of end-stage renal disease (ESRD) Kidney Int 28 1 1985 1 5
4. J. Zaritsky, B. Young, H.J. Wang, and et al. Hepcidin - A potential novel biomarker for iron status in chronic kidney disease Clin J Am Soc Nephrol 4 2009 1051 1056
5. I.C. Macdougall Novel erythropoiesis-stimulating agents: a new era in anemia management Clin J Am Soc Nephrol 3 1 2008 200 207
6. F. Locatelli, and L. Del Vecchio An expert opinion on the current treatment of anemia in patients with kidney disease Expert Opin Pharmacother 13 4 2012 495 503
7. F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol Dial Transplant 22 suppl 4 2007 iv19 iv30
8. S.D. Roger, E. Kolmakova, M. Fung, and et al. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis Nephrology 19 5 2014 266 274
9. M. Sohmiya, T. Kakiba, and Y. Kato Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy Eur J Endocrinol 139 4 1998 367 370
10. S. Salceda, and J. Caro Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J Biol Chem 272 36 1997 22642 22647
11. 2-dependent degradation domain via the ubiquitin-proteasome pathway Proc Natl Acad Sci U S A 95 14 1998 7987 7992
12. M. Nangaku, Y. Izuhara, S. Takizawa, and et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia Arterioscler Thromb Vasc Biol 27 12 2007 2548 2554
13. W.M. Bernhardt, M.S. Wiesener, P. Scigalla, and et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD J Am Soc Nephrol 21 12 2010 2151 2156
14. F.S. Lee, and M.J. Percy The HIF pathway and erythrocytosis Annu Rev Pathol 6 2011 165 192
15. A. Besarab, H.N. Hulter, S. Klaus, and et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemia stage 3/4 CKD patients [abstract] J Am Soc Nephrol 21 2011 95A
16. M.M. Hsieh, N.S. Linde, A. Wynter, and et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques Blood 110 6 2007 2140 2147
17. M. Mastrogiannaki, P. Matak, B. Keith, M.C. Simon, S. Vaulont, and C. Peyssonnaux HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice J Clin Invest 119 5 2009 1159 1166
18. H. Ding, C.Z. Yan, H. Shi, and et al. Hepcidin is involved in iron regulation in the ischemic brain PLoS One 6 9 2011 e25324
19. K. Niihata, N. Tomosugi, T. Uehata, and et al. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease Nephrol Dial Transplant 27 12 2012 4378 4385
20. R.A. Brigandi, S.F. Russ, C. Oei, and et al. Modulation of erythropoietin by prolyl hydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [JASN abstract TH-PO393] J Am Soc Nephrol 23 2011 203A
21. T. Uehata, N. Tomosugi, T. Shoji, and et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study Nephrol Dial Transplant 27 3 2012 1076 1083
22. R.A. Brigandi, S.F. Russ, M. Al-Banna, and et al. Prolyl hydroxylase inhibitior modulation of erythropoietin in a randomized placebo controlled trial [abstract] J Am Soc Nephrol 21 2010 390A
23. R.A. Brigandi, S.F. Russ, C. Oei, and et al. Modulation of erythropoietin by prolyl hydroxylase inhibitor in renal impaired patients in a single dose cross-over study [JASN abstract TH-PO394] J Am Soc Nephrol 23 2011 203A
24. S. Klaus, I. Langsetmo, T. Neff, A. Lin, and D. Liu Beneficial pharmacodynamic effects resulting from 'complete erythropoiesis' induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592 [abstract] J Am Soc Nephrol 19 2008 524A
25. No authors listed. AKB-6548 clinical development. akebia.com/programs/akb-6548/clinical-development/. Accessed September 12, 2014.
26. Q.J. Wang, G. Guo, T. Seeley, and et al. Induction of renal and extra-renal erythropoietin production by orally bioavailable HIF prolyl hydroxylase inhibitors [abstract] J Am Soc Nephrol 16 2005 483A
27. W.M. Bernhardt, M.S. Wiesener, R.E. Schmieder, V. Guenzler, and K.U. Eckardt The prolylhydroxylase inhibitor FG2216 stimulates EPO production in nephric and anephric dialysis patients - evidence for an underutilized production capacity in liver and kidneys [abstract] J Am Soc Nephrol 18 2007 515A